NO20061837L - Bicyclic imino acid derivatives used as inhibitors of matrix metalloproteinases - Google Patents
Bicyclic imino acid derivatives used as inhibitors of matrix metalloproteinasesInfo
- Publication number
- NO20061837L NO20061837L NO20061837A NO20061837A NO20061837L NO 20061837 L NO20061837 L NO 20061837L NO 20061837 A NO20061837 A NO 20061837A NO 20061837 A NO20061837 A NO 20061837A NO 20061837 L NO20061837 L NO 20061837L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- matrix metalloproteinases
- inhibitors
- acid derivatives
- wound healing
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010003246 arthritis Diseases 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- 230000029663 wound healing Effects 0.000 abstract 2
- 208000036487 Arthropathies Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 241000242722 Cestoda Species 0.000 abstract 1
- 208000027932 Collagen disease Diseases 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 206010023204 Joint dislocation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 208000026816 acute arthritis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005499 meniscus Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000004417 patella Anatomy 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 208000005801 spondylosis Diseases 0.000 abstract 1
- 230000036262 stenosis Effects 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forbindelser med formel I egner seg for fremstilling av legemidler for profylakse og behandling av sykdommer ved hvis forløp en forsterket aktivitet av matriksmetalloproteinaser virker inn. Hertil hører sykdommer som degenerativ leddsykdom, eksempelvis osteoartroser, spondyloser, bensvinn etter leddtrauma eller lengre roligstillelse av ledd etter menisk- eller patellaskader eller båndriss, eller en sykdom i bindevevet som kollagenoser, periodontalsykdommer, sårhelingsforstyrrelser, en kronisk sykdom i bevegelsesapparatet som betennelsesfomige, immunologiske eller stoffskiftebetingede akutte eller kroniske artritider, artropatier, myalgier eller forstyrrelser av benstoffskiftet eller en ulcerasjon, aterosklerose eller stenose eller en betennelsesformig sykdom eller en kreftsykdom, tumormetastasedannelse, kakeksi, anoreksi eller septisk sjokk.Compounds of formula I are suitable for the preparation of drugs for the prophylaxis and treatment of diseases in the course of which an enhanced activity of matrix metalloproteinases acts. These include diseases such as degenerative joint disease, such as osteoarthrosis, spondylosis, bone loss after joint trauma or prolonged joint dislocation following meniscus or patella injury or tapeworm, or a disease of the connective tissue such as collagenosis, periodontal disease, wound healing disorders, wound healing disorders metabolic-related acute or chronic arthritis, arthropathies, myalgias or disorders of bone metabolism or an ulcer, atherosclerosis or stenosis or an inflammatory disease or cancer, tumor metastasis, cachexia, anorexia or septic shock.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344936A DE10344936A1 (en) | 2003-09-27 | 2003-09-27 | Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases |
| PCT/EP2004/010248 WO2005030728A1 (en) | 2003-09-27 | 2004-09-14 | Bicyclic imino acid derivatives used as inhibitors of matrix-metalloproteinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061837L true NO20061837L (en) | 2006-06-01 |
Family
ID=34353126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061837A NO20061837L (en) | 2003-09-27 | 2006-04-26 | Bicyclic imino acid derivatives used as inhibitors of matrix metalloproteinases |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1670766B1 (en) |
| JP (1) | JP4861179B2 (en) |
| KR (1) | KR20060086367A (en) |
| CN (1) | CN1856478B (en) |
| AR (1) | AR046165A1 (en) |
| AT (1) | ATE550327T1 (en) |
| AU (1) | AU2004275937A1 (en) |
| BR (1) | BRPI0414594A (en) |
| CA (1) | CA2539731A1 (en) |
| DE (1) | DE10344936A1 (en) |
| IL (1) | IL174040A0 (en) |
| MA (1) | MA28075A1 (en) |
| ME (1) | MEP33008A (en) |
| MX (1) | MXPA06002927A (en) |
| MY (1) | MY139830A (en) |
| NO (1) | NO20061837L (en) |
| NZ (1) | NZ546158A (en) |
| PE (1) | PE20050432A1 (en) |
| RS (1) | RS20060194A (en) |
| RU (1) | RU2335494C2 (en) |
| TW (1) | TW200520755A (en) |
| UY (1) | UY28539A1 (en) |
| WO (1) | WO2005030728A1 (en) |
| ZA (1) | ZA200601501B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004031850A1 (en) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicaments |
| DE102004031620A1 (en) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments |
| DE102005002500A1 (en) * | 2005-01-19 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Tetrahydrofuran derivatives as inhibitors of matrix metalloproteinases |
| DE102005015040A1 (en) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicament |
| US8790714B2 (en) | 2007-08-03 | 2014-07-29 | Nucitec, S.A. De C.V. | Compositions and methods for treatment and prevention of osteoarthritis |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201303B (en) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| FR2701480B1 (en) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them. |
| BR9611479B1 (en) * | 1995-11-13 | 2009-01-13 | Unsubstituted cyclic and heterocyclic alpha-iminohydroxamic and carboxylic acids. | |
| CA2264045A1 (en) * | 1996-08-28 | 1998-03-05 | Randall Stryker Matthews | Heterocyclic metalloprotease inhibitors |
| ATE223909T1 (en) * | 1997-01-23 | 2002-09-15 | Hoffmann La Roche | SULFAMIDE METALLOPROTEASE INHIBITORS |
| DE19719817A1 (en) * | 1997-05-13 | 1998-11-19 | Hoechst Ag | Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids |
| DE10300015A1 (en) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Imino acid derivatives as inhibitors of matrix metal proteinases |
| DE102004031620A1 (en) * | 2004-06-30 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments |
-
2003
- 2003-09-27 DE DE10344936A patent/DE10344936A1/en not_active Withdrawn
-
2004
- 2004-09-14 NZ NZ546158A patent/NZ546158A/en unknown
- 2004-09-14 MX MXPA06002927A patent/MXPA06002927A/en active IP Right Grant
- 2004-09-14 EP EP04786944A patent/EP1670766B1/en not_active Expired - Lifetime
- 2004-09-14 RS YUP-2006/0194A patent/RS20060194A/en unknown
- 2004-09-14 AT AT04786944T patent/ATE550327T1/en active
- 2004-09-14 CA CA002539731A patent/CA2539731A1/en not_active Abandoned
- 2004-09-14 RU RU2006114352/04A patent/RU2335494C2/en not_active IP Right Cessation
- 2004-09-14 AU AU2004275937A patent/AU2004275937A1/en not_active Abandoned
- 2004-09-14 JP JP2006527308A patent/JP4861179B2/en not_active Expired - Fee Related
- 2004-09-14 BR BRPI0414594-1A patent/BRPI0414594A/en not_active IP Right Cessation
- 2004-09-14 KR KR1020067005981A patent/KR20060086367A/en not_active Ceased
- 2004-09-14 ME MEP-330/08A patent/MEP33008A/en unknown
- 2004-09-14 WO PCT/EP2004/010248 patent/WO2005030728A1/en not_active Ceased
- 2004-09-14 CN CN2004800279029A patent/CN1856478B/en not_active Expired - Fee Related
- 2004-09-21 PE PE2004000918A patent/PE20050432A1/en not_active Application Discontinuation
- 2004-09-23 TW TW093128791A patent/TW200520755A/en unknown
- 2004-09-23 AR ARP040103437A patent/AR046165A1/en not_active Application Discontinuation
- 2004-09-25 MY MYPI20043935A patent/MY139830A/en unknown
- 2004-09-27 UY UY28539A patent/UY28539A1/en unknown
-
2006
- 2006-02-21 ZA ZA200601501A patent/ZA200601501B/en unknown
- 2006-03-01 IL IL174040A patent/IL174040A0/en unknown
- 2006-03-27 MA MA28892A patent/MA28075A1/en unknown
- 2006-04-26 NO NO20061837A patent/NO20061837L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MEP33008A (en) | 2010-10-10 |
| RU2006114352A (en) | 2006-08-27 |
| UY28539A1 (en) | 2005-04-29 |
| ATE550327T1 (en) | 2012-04-15 |
| MA28075A1 (en) | 2006-08-01 |
| IL174040A0 (en) | 2006-08-01 |
| DE10344936A1 (en) | 2005-04-21 |
| CN1856478B (en) | 2010-05-26 |
| NZ546158A (en) | 2008-11-28 |
| MY139830A (en) | 2009-10-30 |
| AU2004275937A1 (en) | 2005-04-07 |
| EP1670766A1 (en) | 2006-06-21 |
| EP1670766B1 (en) | 2012-03-21 |
| BRPI0414594A (en) | 2006-11-07 |
| CN1856478A (en) | 2006-11-01 |
| RS20060194A (en) | 2008-08-07 |
| AR046165A1 (en) | 2005-11-30 |
| ZA200601501B (en) | 2007-04-25 |
| TW200520755A (en) | 2005-07-01 |
| PE20050432A1 (en) | 2005-07-21 |
| RU2335494C2 (en) | 2008-10-10 |
| MXPA06002927A (en) | 2006-06-14 |
| KR20060086367A (en) | 2006-07-31 |
| CA2539731A1 (en) | 2005-04-07 |
| JP4861179B2 (en) | 2012-01-25 |
| JP2007506690A (en) | 2007-03-22 |
| WO2005030728A1 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0220187D0 (en) | Organic compounds | |
| GB0121033D0 (en) | Organic compounds | |
| PT1689387E (en) | MEK BICYCLIC INHIBITORS AND THEIR METHODS OF SYNTHESIS | |
| ATE331718T1 (en) | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | |
| WO2005090333A8 (en) | 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases | |
| MXPA03011484A (en) | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease. | |
| NO20044038L (en) | Glutaminyl-based DRIV inhibitors | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| IL187438A0 (en) | Pyrrolopyridine derivatives and pharmaceutical compositions containing the same | |
| WO2007079199A3 (en) | Substituted bis-amide metalloprotease inhibitors | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| DK1625126T3 (en) | Imidazo and thiazolopyridines as JAK3 kinase inhibitors | |
| WO2007011833A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| DK0705254T3 (en) | Phenyl heterocyclic compounds as cyclooxygenase-2 inhibitors | |
| PL367821A1 (en) | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | |
| WO1997018207A3 (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
| NO20071594L (en) | Pyrimidine sulfonamide derivatives as chemokine receptor modulators | |
| CL2004000848A1 (en) | COMPOUNDS DERIVED FROM FENACIL-2-HIDROXI-3-DIAMINOALCANS, INHIBITORS OF THE ENZYME BETASECRETASA, USEFUL TO PREPARE A MEDICINAL PRODUCT TO TREAT ALZHEIMER, DOWN SYNDROME, HEREDITAR CEREBRAL HERIDAL AND OEREDOS | |
| WO2003065987A3 (en) | Granzyme b inhibitors | |
| ITMI20031311A1 (en) | FORMULATIONS FOR THE TREATMENT OF ARTHROSIC DISORDERS. | |
| WO2003028721A3 (en) | Substituted benzimidazole compounds and their use for the treatment of cancer | |
| NO20061837L (en) | Bicyclic imino acid derivatives used as inhibitors of matrix metalloproteinases | |
| AU7385398A (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
| WO2005073236A3 (en) | Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors | |
| WO2006042103A3 (en) | Reversible inhibitors of cathepsin b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |